Tandem Diabetes Care (TNDM) Free Cash Flow (2013 - 2026)

Tandem Diabetes Care has reported Free Cash Flow for 14 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 122.53% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$3.6 million (down 124.39% YoY), and the FY2025 full-year result was -$29.7 million, down 225.11% from the prior year.
• Free Cash Flow for Q1 2026 stood at $4.8 million, up from -$9.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $26.4 million in Q4 2024, with the low at -$22.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$1.2 million across 5 years, with a median of -$5.2 million in 2022.
• The largest YoY upside for Free Cash Flow was 5829.02% in 2023 against a maximum downside of 300.74% in 2023.
• Tandem Diabetes Care's Free Cash Flow stood at $193000.0 in 2022, then jumped by 5829.02% to $11.4 million in 2023, then surged by 130.43% to $26.4 million in 2024, then tumbled by 135.38% to -$9.3 million in 2025, then soared by 151.3% to $4.8 million in 2026.
• The last three Free Cash Flow figures came in at $4.8 million (Q1 2026), -$9.3 million (Q4 2025), and $8.5 million (Q3 2025), per Business Quant data.